PMID- 37950769
OWN - NLM
STAT- MEDLINE
DCOM- 20240506
LR  - 20240515
IS  - 1432-1912 (Electronic)
IS  - 0028-1298 (Print)
IS  - 0028-1298 (Linking)
VI  - 397
IP  - 5
DP  - 2024 May
TI  - Immunoregulatory role of hesperidin against ovalbumin (OVA)-induced bronchial 
      asthma and depression in rats.
PG  - 3363-3378
LID - 10.1007/s00210-023-02833-7 [doi]
AB  - Links between bronchial asthma and depression have recently become a great 
      subject of interest. The present study was carried out to assess the protective 
      role of hesperidin against ovalbumin (OVA)-induced bronchial asthma that is 
      associated with depression in rats, for this purpose, four groups. Rats were 
      sensitized with intraperitoneal administration of 200 mug OVA/10 mg aluminum 
      hydroxide (Al (OH) 3 for 3 consecutive days then at day 11 followed by intranasal 
      challenge with OVA (1.5 mg/kg) at days 19, 20, and 21. Rats were pretreated with 
      hesperidin (100 & 200 mg/kg) 1h before OVA challenge. At the end of the study, 
      behavioral tests, biochemical indices, and histopathological architectures of 
      lung and brain tissues were evaluated. Our findings showed that hesperidin 
      significantly ameliorated the reduction in motor activity, motor coordination, 
      forced swimming, CD4, CD25 and foxp3, interleukin-10 (IL-10), dopamine, 
      serotonin, and neurotrophin-3 (NT3) as well as alleviated the elevation in 
      transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha), 
      iL-5, and immunoglobulin E (IgE). In addition, hesperidin reduced cellular 
      infiltration, alveolar sacs damage, the bronchioles wall disruption, and nuclei 
      pyknosis in neuron cells. Finally, hesperidin may provide protection against 
      OVA-induced asthma and depression. This impact could be mediated in part by its 
      anti-inflammatory and immunoregulatory properties.
CI  - (c) 2023. The Author(s).
FAU - Salama, Abeer
AU  - Salama A
AD  - Pharmacology Department, Medical Research and Clinical Studies Institute, 
      National Research Centre, El-Buhouth St., Dokki, Cairo, 12622, Egypt.
FAU - Gouida, Mona S O
AU  - Gouida MSO
AD  - Genetics Unit, Faculty of Medicine, Children Hospital, Mansoura University, 
      Mansoura, Egypt.
FAU - Yassen, Noha N
AU  - Yassen NN
AD  - Pathology Department, National Research Centre, El-Buhouth St., Dokki, Cairo, 
      12622, Egypt.
FAU - Sedik, Ahmed A
AU  - Sedik AA
AD  - Pharmacology Department, Medical Research and Clinical Studies Institute, 
      National Research Centre, El-Buhouth St., Dokki, Cairo, 12622, Egypt. 
      aa.sedik@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231111
PL  - Germany
TA  - Naunyn Schmiedebergs Arch Pharmacol
JT  - Naunyn-Schmiedeberg's archives of pharmacology
JID - 0326264
RN  - E750O06Y6O (Hesperidin)
RN  - 9006-59-1 (Ovalbumin)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Cytokines)
RN  - 333DO1RDJY (Serotonin)
SB  - IM
MH  - Animals
MH  - *Hesperidin/pharmacology/therapeutic use
MH  - *Asthma/drug therapy/immunology/chemically induced
MH  - *Ovalbumin/immunology
MH  - Male
MH  - *Depression/drug therapy
MH  - *Rats, Wistar
MH  - *Lung/drug effects/pathology/immunology/metabolism
MH  - Rats
MH  - Immunoglobulin E/blood
MH  - Brain/drug effects/metabolism/pathology/immunology
MH  - Motor Activity/drug effects
MH  - Cytokines/metabolism
MH  - Behavior, Animal/drug effects
MH  - Serotonin/metabolism
MH  - Disease Models, Animal
PMC - PMC11074047
OTO - NOTNLM
OT  - Bronchial asthma
OT  - Depression
OT  - Hesperidin
OT  - Ovalbumin
COIS- The authors declare no competing interests.
EDAT- 2023/11/11 20:46
MHDA- 2024/05/06 12:44
PMCR- 2023/11/11
CRDT- 2023/11/11 11:04
PHST- 2023/06/29 00:00 [received]
PHST- 2023/11/01 00:00 [accepted]
PHST- 2024/05/06 12:44 [medline]
PHST- 2023/11/11 20:46 [pubmed]
PHST- 2023/11/11 11:04 [entrez]
PHST- 2023/11/11 00:00 [pmc-release]
AID - 10.1007/s00210-023-02833-7 [pii]
AID - 2833 [pii]
AID - 10.1007/s00210-023-02833-7 [doi]
PST - ppublish
SO  - Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3363-3378. doi: 
      10.1007/s00210-023-02833-7. Epub 2023 Nov 11.